Hypera Pharma
Hypera Pharma, a leading player in the Brazilian pharmaceutical industry, is headquartered in São Paulo, Brazil. Founded in 2010, the company has rapidly established itself as a key provider of prescription and over-the-counter medications, focusing on therapeutic areas such as central nervous system disorders, dermatology, and consumer health. With a diverse portfolio of well-known brands, Hypera Pharma distinguishes itself through its commitment to innovation and quality, ensuring that its products meet the highest standards. The company has achieved significant market presence, becoming one of the largest pharmaceutical companies in Brazil, and has garnered recognition for its strategic acquisitions and robust growth trajectory. Hypera Pharma continues to enhance its position in the industry by prioritising research and development, aiming to improve health outcomes for patients across the region.
DitchCarbon Score
How does Hypera Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hypera Pharma's score of 29 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hypera Pharma's reported carbon emissions
Hypera Pharma, headquartered in Brazil, reported its carbon emissions for 2021 at approximately 50,202,930 kg CO2e. This total includes 25,417,550 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 8,665,850 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. Additionally, the company recorded 16,119,530 kg CO2e in Scope 3 emissions, which cover all other indirect emissions in the value chain. Hypera Pharma has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2020 as the base year. This target has been validated by the Science Based Targets initiative (SBTi) and aligns with the goal of limiting global warming to 1.5°C. The company also plans to measure and reduce its Scope 3 emissions, demonstrating a comprehensive approach to tackling its overall carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Scope 1 | 19,561,440 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 4,925,500 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 17,458,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hypera Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
